Ongoing Clinical Trials for Deep Vein Thrombosis Postoperative
Currently, there is 1 ongoing clinical trial investigating treatments for patients who have experienced blood clots following surgery or other medical events. This trial is examining whether rosuvastatin, a medication commonly used to manage cholesterol, can help prevent recurring blood clots in patients with deep vein thrombosis or pulmonary embolism. The study is being conducted in France and Norway.
Clinical trial locations
- France
- Norway
Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism
This clinical trial is investigating whether rosuvastatin calcium can help prevent blood clots from returning in patients who have already experienced certain types of clotting problems. The study focuses on patients with blood clots in the deep veins of the legs or blockages in the lung arteries.
Who can participate:
To join this trial, patients must have a confirmed diagnosis of a blood clot in the deep veins of the upper leg or a blockage in the lung arteries that occurred within the last 30 days. Both men and women showing symptoms of these conditions are eligible to participate.
Who cannot participate:
The study excludes several groups of people to ensure safety. Pregnant or breastfeeding women cannot join. Patients with severe liver or kidney disease, those with a history of severe allergic reactions to the study medication, and individuals currently taking medications that might interfere with the treatment are not eligible. People with recent major surgery, uncontrolled high blood pressure, significant bleeding problems, certain heart rhythm issues, or a history of alcohol or drug abuse are also excluded. Additionally, those who cannot follow the study procedures or attend scheduled visits cannot participate.
What the trial involves:
Participants will be randomly assigned to receive either rosuvastatin calcium (in a 20 mg tablet taken by mouth) or a placebo, which is an inactive substance. This randomization ensures the study results are unbiased. Throughout the trial, participants will be regularly monitored for any signs of recurring blood clots in the legs or lungs, as well as other health events such as heart attacks or strokes. The study also examines whether participants develop post-thrombotic syndrome, a condition that can occur after a blood clot. The trial is expected to continue until the end of 2027.
The investigational drug:
Rosuvastatin is a medication typically used to lower cholesterol levels. In this trial, researchers are testing whether it can help prevent blood clots from returning. The drug works by blocking an enzyme involved in cholesterol production in the liver, which may also reduce inflammation and help stabilize blood vessel walls.
Summary
There is currently one active clinical trial for patients who have experienced postoperative deep vein thrombosis. The trial is being conducted in two European countries, France and Norway, and focuses on testing rosuvastatin calcium as a potential preventive treatment against recurring blood clots. The study represents an important effort to explore whether medications traditionally used for cholesterol management might offer additional benefits in preventing serious clotting events. Patients interested in participating should discuss eligibility with their healthcare providers, keeping in mind the specific inclusion and exclusion criteria outlined in the trial.
